Abstract
The most important properties of a protein are determined by its primary structure, its amino acid sequence. However, protein features can be also modified by a large number of posttranslational modifications. These modifications can occur during or after the synthesis process, and glycosylation appears as the most common posttranslational modification. It is estimated that 50 % of human proteins have some kind of glycosylation, which has a key role in maintaining the structure, stability, and function of the protein. Besides, glycostructures can also influence the pharmacokinetics and immunogenicity of the protein. Although the glycosylation process is a conserved mechanism that occurs in yeast, plants, and animals, several studies have demonstrated significant differences in the glycosylation pattern in recombinant proteins expressed in mammalian, yeast, and insect cells. Thus, currently, important efforts are being done to improve the systems for the expression of recombinant glycosylated proteins. Among the different mammalian cell lines used for the production of recombinant proteins, a significant difference in the glycosylation pattern that can alter the production and/or activity of the protein exists. In this context, human cell lines have emerged as a new alternative for the production of human therapeutic proteins, since they are able to produce recombinant proteins with posttranslational modifications similar to its natural counterpart and reduce potential immunogenic reactions against nonhuman epitopes. This chapter describes the steps necessary to produce a recombinant glycoprotein in a human cell line in small scale and also in bioreactors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Leavitt R, Schlesinger S, Kornfeld S (1977) Impaired intracellular migration and altered solubility of nonglycosylated glycoproteins of vesicular stomatitis virus and Sindbis virus. J Biol Chem 252:9018–9023
Wallick SC, Kabat EA, Morrison SL (1988) Glycosylation of a VH residue of a monoclonal antibody against alpha (1–6) dextran increases its affinity for antigen. J Exp Med 168:1099–1109
Walsh MT, Watzlawick H, Putnam FW et al (1990) Effect of the carbohydrate moiety on the secondary structure of beta 2-glycoprotein. I. Implications for the biosynthesis and folding of glycoproteins. Biochemistry 29:6250–6257
Croset A, Delafosse L, Gaudry JP et al (2012) Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. J Biotechnol 161:336–348
Gemmill TR, Trimble RB (1999) Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochim Biophys Acta 1426:227–237
Gomord V, Chamberlain P, Jefferis R et al (2005) Biopharmaceutical production in plants: problems, solutions and opportunities. Trends Biotechnol 23:559–565
Russo-Carbolante EM, Picanco-Castro V, Alves DC et al (2011) Integration pattern of HIV-1 based lentiviral vector carrying recombinant coagulation factor VIII in Sk-Hep and 293T cells. Biotechnol Lett 33:23–31
Schroder AR, Shinn P, Chen H et al (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521–529
Ambrosi A, Cattoglio C, Di Serio C (2008) Retroviral integration process in the human genome: is it really non-random? A new statistical approach. PLoS Comput Biol 4:e1000144. doi:10.1371/journal.pcbi.1000144
Wu X, Li Y, Crise B et al (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 2300:1749–1751
Appelt JU, Giordano FA, Ecker M et al (2009) QuickMap: a public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Ther 16:885–893
Varki A (1998) Factors controlling the glycosylation potential of the Golgi apparatus. Trends Cell Biol 8:34–40
Gross V, Heinrich PC, vom Berg D et al (1988) Involvement of various organs in the initial plasma clearance of differently glycosylated rat liver secretory proteins. Eur J Biochem 173:653–659
Rudd PM, Wormald MR, Wing DR et al (2001) Prion glycoprotein: structure, dynamics, and roles for the sugars. Biochemistry 40:3759–3766
Peter-Katalinic J (2005) Methods in enzymology: O-glycosylation of proteins. Methods Enzymol 405:139–171
Spiro RG (2002) Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12:43R–56R
Hua S, Nwosu CC, Strum JS et al (2012) Site-specific protein glycosylation analysis with glycan isomer differentiation. Anal Bioanal Chem 403:1291–1302
Rajagopalan L, Organ-Darling LE, Liu H et al (2010) Glycosylation regulates prestin cellular activity. J Assoc Res Otolaryngol 11:39–51
Gornik O, Lauc G (2008) Glycosylation of serum proteins in inflammatory diseases. Dis Markers 25:267–278
Cooke CL, An HJ, Kim J et al (2009) Modification of gastric mucin oligosaccharide expression in rhesus macaques after infection with Helicobacter pylori. Gastroenterology 137:1061–1071
Dennis JW, Granovsky M, Warren CE (1999) Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1473:21–34
Ohtsubo K, Marth JD (2006) Glycosylation in cellular mechanisms of health and disease. Cell 126:855–867
Ghaderi D, Taylor RE, Padler-Karavani V et al (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 28:863–867
Galili U (2004) Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. Transplantation 78:1093–1098
Bardor M, Nguyen DH, Diaz S et al (2005) Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 280:4228–4237
Suttie JW, Preusch PC (1986) Studies of the vitamin K-dependent carboxylase and vitamin K epoxide reductase in rat liver. Haemostasis 16:193–215
Chapple SD, Crofts AM, Shadbolt SP et al (2006) Multiplexed expression and screening for recombinant protein production in mammalian cells. BMC Biotechnol 6:49
Fallaux FJ, Bout A, van der Velde I et al (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9:1909–1917
Jones D, Kroos N, Anema R et al (2003) High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol Prog 19:163–168, PubMed PMID: 12573020
Acknowledgment
We would like to thank Sandra Navarro for drawing the figure.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Swiech, K., de Freitas, M.C.C., Covas, D.T., Picanço-Castro, V. (2015). Recombinant Glycoprotein Production in Human Cell Lines. In: García-Fruitós, E. (eds) Insoluble Proteins. Methods in Molecular Biology, vol 1258. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2205-5_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2205-5_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2204-8
Online ISBN: 978-1-4939-2205-5
eBook Packages: Springer Protocols